On January 22, 2020 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported that the company will participate in the Precision Medicine World Conference (PMWC) 2020 in Santa Clara, CA January 22-24 (Press release, Personalis, JAN 22, 2020, View Source [SID1234553421]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation titled "Enabling Advanced Composite Biomarkers for Precision Oncology and Cancer Diagnostics," will describe the Personalis universal cancer immunogenomics platform, ImmunoID NeXT. Richard Chen, MS, MD, Chief Scientific Officer, will present for Personalis. Dr. Chen will provide an overview of how the platform can be used to explore critical immunotherapy-related resistance mechanisms and novel composite biomarkers of response utilizing analytics, including human leukocyte antigen (HLA) typing and HLA loss of heterozygosity (LOH), neoantigen prediction and load, immune repertoire characterization, oncoviral detection, as well as the evaluation of tumor mutational burden (TMB) and microsatellite instability (MSI) status.
ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a single tumor specimen.
Personalis will also be exhibiting during the conference (Exhibit #D2820). Representatives will be available to answer questions about the company’s cancer immunogenomics capabilities.